14348-38-0

Usage

Uses

Used in Pharmaceutical Industry:
4-BROMO-3-HYDROXYBENZOIC ACID is used as a brocresine metabolite for its role in the inhibition of rat fetal and rat gastric histidine decarboxylase. This application is significant in the development of drugs targeting specific metabolic pathways and enzyme inhibition, potentially leading to therapeutic benefits in various medical conditions.
Used in Chemical Synthesis:
As a rust solid with distinct chemical properties, 4-BROMO-3-HYDROXYBENZOIC ACID can be utilized as a key intermediate in the synthesis of various organic compounds and pharmaceuticals. Its unique structure allows for further functionalization and modification, making it a valuable building block in the creation of new molecules with specific applications.
Used in Research and Development:
4-BROMO-3-HYDROXYBENZOIC ACID serves as an important compound in the field of research and development, particularly in the study of enzyme inhibition and the development of novel inhibitors. Its unique structure and properties make it a valuable tool for understanding complex biological processes and designing new therapeutic agents.
Used in Material Science:
The rust solid form of 4-BROMO-3-HYDROXYBENZOIC ACID may have potential applications in material science, particularly in the development of new materials with specific properties. Its unique chemical structure could contribute to the creation of materials with enhanced characteristics, such as improved stability, reactivity, or selectivity in various chemical processes.

InChI:InChI=1/C7H5BrO3/c8-5-2-1-4(7(10)11)3-6(5)9/h1-3,9H,(H,10,11)

Upstream product

• 99-06-9 3-Carboxyphenol 
• 2374-03-0 4-aminosalicylic acid 
• 22921-68-2 2-bromo-5-methoxy-benzoic acid 
• 56-23-5 tetrachloromethane 
• 7726-95-6 bromine 
• 67-66-3 chloroform 
• 64-19-7 acetic acid 
• 42860-06-0 4-bromo-3-iodobenzoic acid 
• 887757-36-0 4-bromo-3-(methoxymethoxy)benzoic acid 
• 56256-14-5 4-bromo-3-methoxy-benzoic acid 

Downstream Products

• 106291-80-9 methyl 4-bromo-3-hydroxybenzoate 
• 99-50-3 3,4-Dihydroxybenzoic acid 
• 79302-44-6 4-bromo-3-trimethylsiloxybenzoic acid trimethylsilyl ester 
• 124318-23-6 3-Benzyloxy-4-brombenzoesaeure-benzylester 
• 17054-27-2 4-bromo-3-benzyloxybenzoic acid 
• 870779-63-8 methyl 4-bromo-3-(tetrahydropyran-2-yloxy)benzoate 
• 870779-64-9 4-bromo-3-(tetrahydropyran-2-yloxy)benzyl alcohol 
• 870779-65-0 4-bromo-3-(tetrahydropyran-2-yloxy)benzyl bromide 
• 870779-66-1 4-{[4-bromo-3-(tetrahydropyran-2-yloxy)benzyl][1,2,4]triazol-4-ylamino}benzonitrile 
• 870779-67-2 4-[(4-bromo-3-hydroxybenzyl)(4-cyanophenyl)amino]-4H-[1,2,4]triazole 
• 79302-57-1 4-bromo-3-(trimethylsiloxy)benzoyl chloride 
• 124318-24-7 3-Benzyloxy-4-(3-formylphenoxy)benzoesaeure-benzylester 
• 114728-16-4 Pakyonol 
• 124318-22-5 17-O-Benzylpakyonol 

Relevant academic research and scientific papers

Rim-functionalized cryptophane-111 derivatives via heterocapping, and their xenon complexes

Capping of cyclotriphenolene (3a) by the more available cyclotriguaiacylene (3c) or trisbromocyclotriphenolene (3b) gives the first rim-functionalized cryptophane-111 derivatives. Crystal structures of the xenon complexes reveal high cavity packing coeffi

Synthesis of a triethylene glycol-capped benzo[1,2-c:4,5-c']bis[2]benzopyran-5,12-dione: A highly soluble dilactone-bridged p-terphenyl with a crankshaft architecture

3,10-Bis(triethylene glycol)benzo[1,2-c:4,5-c']bis[2]benzopyran-5,12-dione has been synthesized as an example of a dilactone-bridged p-terphenyl with a C2h crankshaft architecture that exhibits significant fluorescence. Lactone-bridged rotation

The effect of carboxylate position on the structure of a metal organic framework derived from cyclotriveratrylene

Two cyclotriveratrylene-based ligands H3L1 and H3L2 have been synthesised using microwave heating and used in the formation of 1 [Zn2(L1)(DMA)2(CH3COO)] and 2 [Zn

Total Synthesis of Benzofuran-Based Aspergillusene B via Halogenative Aromatization of Enones

A novel "non-aromatic pool" synthetic strategy for the synthesis of benzofuran-based natural products via oxidative haloaromatization of enones is reported. This approach is successfully applied in the first total synthesis of the natural product aspergil

Copper and L-(?)-quebrachitol catalyzed hydroxylation and amination of aryl halides under air

L-(?)-Quebrachitol, a natural product obtained from waste water of the rubber industry, was utilized as an efficient ligand for the copper-catalyzed hydroxylation and amination of aryl halides to selectively give phenols and aryl amines in water or 95percent ethanol. In addition, the hydroxylation of 2-chloro-4-hydroxybenzoic acid was validated on a 100-g scale under air.

Elongated and substituted triazine-based tricarboxylic acid linkers for MOFs

New triazine-based tricarboxylic acid linkers were prepared as elongated relatives of triazinetribenzoic acid (TATB). Additionally, functional groups (NO2, NH2, OMe, OH) were introduced for potential post-synthetic modification (PSM) of MOFs. Functionalized tris(4-bromoaryl)triazine "cores" (3a,3b) were obtained by unsymmetric trimerization mixing one equivalent of an acid chloride (OMe or NO2 substituted) with two equivalents of an unsubstituted nitrile. Triple Suzuki coupling of the cores 3 with suitable phenyl- and biphenylboronic acid derivatives provided elongated tricarboxylic acid linkers as carboxylic acids 17 and 20 or their esters 16 and 19. Reduction of the nitro group and cleavage of the methoxy group gave the respective amino and hydroxy-substituted triazine linkers.

VIRAL POLYMERASE INHIBITORS

The present application provides compounds of formula I wherein X, Y, R2, n, R5 and R6 are defined herein, useful as inhibitors of the hepatitis C virus NS5B polymerase The present application also provides pharmaceutical

The P1 N-isopropyl motif bearing hydroxyethylene dipeptide isostere analogues of aliskiren are in vitro potent inhibitors of the human aspartyl protease renin

Novel nonpeptide small molecule renin inhibitors bearing an N-isopropyl P1 motif were designed based on initial lead structures 1 and aliskiren (2). (P3-P1)-Benzamide derivatives such as 9a and 34, as well as the corresponding P1 basic tertiary amine derivatives 10 and 35 were found to display low nanomolar inhibition against human renin in vitro.

2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION

The present invention has its object to provide a 2,3,4,5-tetrahydro-1H-1,5-benzodiazepine derivative represented with the Formula (1) , or the pharmaceutically acceptable salt, which is effective as a therapeutic and prophylactic agent for diabetes, diabetic nephropathy, or glomerulosclerosis.

NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE AT1 AND ETA RECEPTORS

The present invention relates to new compounds of the formula [Chemical formula should be inserted here. Please see paper copy] wherein R1, R2, R3, and R31 are as specified herein. The invention also relates to a method for preparation thereof, as well as combinations of the new compounds with previously known agents. The invention also relates to the use of the above-mentioned compounds and combinations for the preparation of a medicament for treating hypertension of different kinds, alleviating organ damage of different kinds, treating or preventing diabetic nephropathy, treating endothelin and angiotensin mediated disorders, and treating prostate cancer.